Correction to: Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (Advances in Therapy, (2019), 36, 10, (2910-2926), 10.1007/s12325-019-01052-y)

Marilyn K. Glassberg, Steven D. Nathan, Chin Yu Lin, Elizabeth A. Morgenthien, John L. Stauffer, Willis Chou, Paul W. Noble

Research output: Contribution to journalComment/debatepeer-review

Fingerprint

Dive into the research topics of 'Correction to: Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (Advances in Therapy, (2019), 36, 10, (2910-2926), 10.1007/s12325-019-01052-y)'. Together they form a unique fingerprint.

Medicine & Life Sciences